StreetInsider.com News Articles

WBB Securities Starts CytoSorbents (CTSO) at Speculative Buy

Wed, 21 Oct 2026 07:24:43 -0400

WBB Securities analyst Karen Sterling initiates coverage on CytoSorbents (NASDAQ: CTSO) with a Speculative Buy rating and a price target of $9.50.

The analyst comments "After facing regulatory and financial challenges in 2025, which caused a delayed timeline for the Company’s market expansion efforts and a substantial drop in its share price, CytoSorbents is emerging as a turnaround story with significant upside potential going into 2027. Management successfully restructured the business in 2026, reducing cash burn to near-breakeven levels in Q2 2026 and streamlining manufacturing. We anticipate seeing operating cash flow breakeven during Q4 2026 and a resumption of core revenue

WBB Securities Starts CytoSorbents (CTSO) at Speculative Buy

Wed, 21 Oct 2026 07:24:43 -0400

WBB Securities analyst Karen Sterling initiates coverage on CytoSorbents (NASDAQ: CTSO) with a Speculative Buy rating and a price target of $9.50.

CytoSorbents to present CytoSorb data at two European conferences

Wed, 30 Sep 2026 07:03:09 -0400

CytoSorbents Corporation (NASDAQ: CTSO) announced it will present clinical data on its CytoSorb blood purification device at two international medical conferences in Europe in October 2026, according to a company press release.

The first event is the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Barcelona, Spain, running October 7–10, 2026. Four presentations are scheduled, covering topics including the use of hemoadsorption to reduce bleeding in coronary artery bypass grafting, treatment of postoperative vasoplegia, hemoadsorption during VA-ECMO, and outcomes in high-risk heart transplant patients. Presenters include Prof. Michael Schmoeckel of Ludwig Maximilian University in Munich, Prof. Federico Papallardo of San

CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care

Wed, 30 Sep 2026 07:00:00 -0400

PRINCETON, N.J., Sept. 30, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces upcoming data presentations using CytoSorb® in open heart surgery at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Barcelona, Spain from October 7-10, 2026 and in critical care at the European Society of Intensive Care Medicine (ESICM) Annual Congress

CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care

Wed, 30 Sep 2026 07:00:00 -0400

Form 8-K Cytosorbents Corp For: Sep 22

Wed, 23 Sep 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260923/27093343.html

CytoSorbents regains Nasdaq minimum bid price compliance

Wed, 23 Sep 2026 07:00:46 -0400

CytoSorbents Corporation (NASDAQ: CTSO) said it received notification from Nasdaq's Listing Qualifications Department on September 22, 2026, that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

The Princeton, N.J.-based medical device company said its common stock closed at or above $1.00 per share for 10 consecutive trading sessions ending September 21, 2026, satisfying the requirement. Nasdaq said the matter is now closed.

The company still faces a separate compliance issue related to the minimum Market Value of Listed Securities requirement under Nasdaq Listing Rule 5550(b)(2), with a compliance deadline of December 28, 2026.

Chief Executive Officer

CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement

Wed, 23 Sep 2026 07:00:00 -0400

PRINCETON, N.J., Sept. 23, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has regained compliance with the Nasdaq Stock Market's minimum bid price requirement of $1.00 per share.

CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement

Wed, 23 Sep 2026 07:00:00 -0400

Form 4 Cytosorbents Corp For: Sep 15 Filed by: Chan Phillip P.

Wed, 16 Sep 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260916/27071255.html

Form 4 Cytosorbents Corp For: Sep 14 Filed by: Capponi Vincent

Wed, 16 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260916/27070286.html

Form 4 Cytosorbents Corp For: Sep 15 Filed by: Sobel Alan D.

Wed, 16 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260916/27070277.html

CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 07:00:00 -0400

PRINCETON, N.J., Sept. 10, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14–16, 2026, in New York City. Dr. Phillip Chan, Chief Executive Officer and Peter Mariani, Chief Financial Officer of CytoSorbents will be attending the conference, joining Sean Lee, Vice President, Equity Research at

CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 07:00:00 -0400

CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Fri, 04 Sep 2026 09:09:00 -0400

Princeton, New Jersey--(Newsfile Corp. - September 4, 2026) - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026, in New York City. Dr. Phillip Chan, CEO and Peter Mariani, CFO will be attending the conference, delivering an investor presentation and participating in scheduled 1-on-1 meetings with investors.

Investor Presentation:
Date: Thursday, September 10, 2026
Time: 2:50pm EST
Location: The Westin New York

CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Fri, 04 Sep 2026 09:09:00 -0400

Investor Presentation:
Date: Thursday, September 10, 2026
Time: 2:50pm EST
Location: The Westin New York

CytoSorbents reports real-world data on bleeding reduction in cardiac surgery

Wed, 02 Sep 2026 07:39:26 -0400

CytoSorbents Corporation (NASDAQ: CTSO) announced results from an independent patient-level matched analysis of real-world data showing that intraoperative use of its CytoSorb device was associated with a 37% relative reduction in severe bleeding among patients undergoing urgent coronary artery bypass grafting (CABG) surgery while on ticagrelor, a blood-thinning medication.

The findings were presented at the European Society of Cardiology Congress on August 29, 2026. The analysis included 587 patients undergoing urgent CABG surgery after recent ticagrelor exposure. Patients treated with CytoSorb (198) from the STAR-T Registry were compared with matched patients (389) who underwent surgery without the device.

The analysis showed a

CytoSorbents reports real-world data on bleeding reduction in cardiac surgery

Wed, 02 Sep 2026 07:39:26 -0400

The analysis showed a

Form 8-K Cytosorbents Corp For: Aug 13

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930343.html

Form 8-K Cytosorbents Corp For: Aug 13

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930343.html

Form 8-K Cytosorbents Corp For: Aug 06

Fri, 07 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260807/26891032.html

Form 8-K Cytosorbents Corp For: Aug 06

Fri, 07 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260807/26891032.html

Cytosorbents (CTSO) Misses Q2 EPS by 1c

Thu, 06 Aug 2026 18:12:01 -0400

Cytosorbents (NASDAQ: CTSO) reported Q2 EPS of ($0.05), $0.01 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $9.63 million versus the consensus estimate of $9.42 million.

For earnings history and earnings-related data on Cytosorbents (CTSO) click here.

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

Thu, 06 Aug 2026 16:25:00 -0400

Highlighting Four Independent Drivers of Shareholder Value

PRINCETON, N.J., Aug. 6, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2026, recent business highlights, and provides a regulatory update.

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

Thu, 06 Aug 2026 16:25:00 -0400

Highlighting Four Independent Drivers of Shareholder Value